Showing 7531-7540 of 9496 results for "".
- Exosome Update: Evolve Skincare to Distribute Elevai Skin Care Products in Canadahttps://practicaldermatology.com/news/exosome-update-evolve-skincare-to-distribute-elevai-skin-care-products-in-canada/2461572/Evolve Medical Inc. is the exclusive distributor for Elevai Skincare products in Canada. The Elevai E-Series product range, a pre-and post-procedure skincare system developed with a proprietary stem cell exosome technology, will now be available to dermatologists
- Celluma Light Therapy Headquarters Moves to Tustin, Californiahttps://practicaldermatology.com/news/celluma-light-therapy-headquarters-moves-to-tustin-calif/2461570/BioPhotas, Inc., the maker of the Celluma Series of light therapy devices, is moving its corporate headquarters and manufacturing operations from Anaheim to Tustin, Calif. The new headquarters boasts 25,000 square feet of office and warehouse space, facilitating continued gro
- Dove Partners with LinkedIn in Effort to Help End Race-Based Hair Discrimination in the Workplacehttps://practicaldermatology.com/news/dove-partners-with-linkedin-in-effort-to-help-end-race-based-hair-discrimination-in-the-workplace/2461566/In an effort to help pass “The CROWN Act,” which aims to end race-based hair discrimination, Dove announced it is partnering with LinkedIn. The NEW CROWN 2023 Workplace Research Study, co-commissioned by Dove and LinkedIn, found that black women's hair is 2.5x more
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- La Roche-Posay Gives Back: Brand Supports USC's Skin of Color and Pigmentary Disorders Research Fellowshiphttps://practicaldermatology.com/news/la-roche-posay-gives-back-brand-supports-uscs-skin-of-color-and-pigmentary-disorders-research-fellowship/2461558/La Roche-Posay is supporting the Skin of Color and Pigmentary Disorders Research Fellowship at the Keck School of Medicine of University of Southern California (USC). The fellowship allows students, between their third and fourth years of medical school, the opportunity to con
- Povorcitinib Produces Lasting Results in HShttps://practicaldermatology.com/news/povorcitinib-produces-lasting-results-in-hs/2461557/Longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms in a phase 2 study of hidradenitis suppurativa (HS) patients. Povorcitinib is an oral JAK1 inhibitor. These data were presented as an oral presentation at th
- Medical Groups Offer Updated Guidance on Hand Hygiene in Healthcare Settingshttps://practicaldermatology.com/news/groups-offer-updated-guidance-on-hand-hygiene-in-healthcare-settings/2461551/Five medical organizations are recommending updated best practices for hand hygiene to protect patients and staff in healthcare settings. The new recommendations emphasize the importance of healthy skin and nails and easy access to alcohol-based hand sanitizers. Strategi
- Study: Six Percent of Children Have Eczema Symptoms Worldwidehttps://practicaldermatology.com/news/study-six-percent-of-children-have-eczema-symptoms-worldwide/2461550/About 6% of children and adolescents have some form of eczema, according to New research published in Clinical & Experimental Allergy. In addition, 0.6% of children and 1.1% of adolescents across the g
- Meet TargetCool, CoolHealth's Solution to Post-Procedure Pain, Bruisinghttps://practicaldermatology.com/news/meet-targetcool-coolhealths-solution-to-post-procedure-pain-bruising/2461549/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and
- MTX Use May Up Risk for Three Types of Skin Cancerhttps://practicaldermatology.com/news/mtx-use-may-up-skin-cancer-risk/2461546/Methotrexate (MTX) may increase risk for three types of skin cancer, according to a new study out of University of Gothenburg. Patients receiving the drug include those with moderate to severe psoriasis; but in this particular patient group, a risk increase was only observed for basal c